Health Trials

About this trial

To quantify genetic variants in a focused DCM gene panel among AF-induced cardiomyopathy (AIC) and positive/negative controls

Eligibility criteria

Qualifiers

Age ≥18

Persistent AF before index catheter ablation or cardioversion

LVEF ≤40% during rate-controlled (resting HR <100bpm, mean HR on 24-hour Holter <100bpm) AF prior to index catheter ablation or cardioversion

LVEF normalisation (LVEF ≥55%) in SR, post-catheter ablation or cardioversion (≥3 months post-catheter ablation or cardioversion), no AF (>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation), and with no new introduction of any new or increased dose of heart failure guideline-directed medical therapy (GDMT) (renin-angiotensin-aldosterone system inhibitors (RAASi), Sodium Glucose Co-transporter 2 (SLGT2) inhibitors, increased dose of beta-blocker (BB), mineralocorticoid receptor antagonist (MRA))

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

299 Participants
are grouped into 3 trial groups

Locations

1
St Bartholomew's Hospital, Barts Health NHS TrustEC1A 7BE, London United Kingdom

Sponsors and collaborators

Barts & The London NHS Trust

Lead sponsor

Source ClinicalTrials.gov